Cancer Incidence and Survival Trends by Subtype Using Data from the Surveillance Epidemiology and End Results Program, 1992-2013
Cancers are heterogeneous, comprising distinct tumor subtypes. Therefore, presenting the burden of cancer in the population and trends over time by these tumor subtypes is important to identify patterns and differences in the occurrence of these subtypes, especially to generalize findings to the U.S...
Uložené v:
| Vydané v: | Cancer epidemiology, biomarkers & prevention Ročník 26; číslo 4; s. 632 |
|---|---|
| Hlavní autori: | , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
01.04.2017
|
| Predmet: | |
| ISSN: | 1538-7755, 1538-7755 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Cancers are heterogeneous, comprising distinct tumor subtypes. Therefore, presenting the burden of cancer in the population and trends over time by these tumor subtypes is important to identify patterns and differences in the occurrence of these subtypes, especially to generalize findings to the U.S. general population.
Using SEER Cancer Registry Data, we present incidence rates according to subtypes for diagnosis years (1992-2013) among men and women for five major cancer sites: breast (female only), esophagus, kidney and renal pelvis, lung and bronchus, and thyroid. We also describe estimates of 5-year relative survival according to subtypes and diagnosis year (1992-2008). We used Joinpoint models to identify years when incidence rate trends changed slope. Finally, recent 5-year age-adjusted incidence rates (2009-2013) are presented for each subtype by race and age.
Hormone receptor-positive and HER2-negative was the most common subtype (about 74%) of breast cancers. Adenocarcinoma made up about 69% of esophagus cases among men. Adenocarcinoma also is the most common lung subtype (43% in men and 52% in women). Ninety percent of thyroid subtypes were papillary. Distinct incidence and survival patterns emerged by these subtypes over time among men and women.
Histologic or molecular subtype revealed different incidence and/or survival trends that are masked when cancer is considered as a single disease on the basis of anatomic site.
Presenting incidence and survival trends by subtype, whenever possible, is critical to provide more detailed and meaningful data to patients, providers, and the public.
. |
|---|---|
| AbstractList | Background: Cancers are heterogeneous, comprising distinct tumor subtypes. Therefore, presenting the burden of cancer in the population and trends over time by these tumor subtypes is important to identify patterns and differences in the occurrence of these subtypes, especially to generalize findings to the U.S. general population.Methods: Using SEER Cancer Registry Data, we present incidence rates according to subtypes for diagnosis years (1992-2013) among men and women for five major cancer sites: breast (female only), esophagus, kidney and renal pelvis, lung and bronchus, and thyroid. We also describe estimates of 5-year relative survival according to subtypes and diagnosis year (1992-2008). We used Joinpoint models to identify years when incidence rate trends changed slope. Finally, recent 5-year age-adjusted incidence rates (2009-2013) are presented for each subtype by race and age.Results: Hormone receptor-positive and HER2-negative was the most common subtype (about 74%) of breast cancers. Adenocarcinoma made up about 69% of esophagus cases among men. Adenocarcinoma also is the most common lung subtype (43% in men and 52% in women). Ninety percent of thyroid subtypes were papillary. Distinct incidence and survival patterns emerged by these subtypes over time among men and women.Conclusions: Histologic or molecular subtype revealed different incidence and/or survival trends that are masked when cancer is considered as a single disease on the basis of anatomic site.Impact: Presenting incidence and survival trends by subtype, whenever possible, is critical to provide more detailed and meaningful data to patients, providers, and the public. Cancer Epidemiol Biomarkers Prev; 26(4); 632-41. ©2016 AACR.Background: Cancers are heterogeneous, comprising distinct tumor subtypes. Therefore, presenting the burden of cancer in the population and trends over time by these tumor subtypes is important to identify patterns and differences in the occurrence of these subtypes, especially to generalize findings to the U.S. general population.Methods: Using SEER Cancer Registry Data, we present incidence rates according to subtypes for diagnosis years (1992-2013) among men and women for five major cancer sites: breast (female only), esophagus, kidney and renal pelvis, lung and bronchus, and thyroid. We also describe estimates of 5-year relative survival according to subtypes and diagnosis year (1992-2008). We used Joinpoint models to identify years when incidence rate trends changed slope. Finally, recent 5-year age-adjusted incidence rates (2009-2013) are presented for each subtype by race and age.Results: Hormone receptor-positive and HER2-negative was the most common subtype (about 74%) of breast cancers. Adenocarcinoma made up about 69% of esophagus cases among men. Adenocarcinoma also is the most common lung subtype (43% in men and 52% in women). Ninety percent of thyroid subtypes were papillary. Distinct incidence and survival patterns emerged by these subtypes over time among men and women.Conclusions: Histologic or molecular subtype revealed different incidence and/or survival trends that are masked when cancer is considered as a single disease on the basis of anatomic site.Impact: Presenting incidence and survival trends by subtype, whenever possible, is critical to provide more detailed and meaningful data to patients, providers, and the public. Cancer Epidemiol Biomarkers Prev; 26(4); 632-41. ©2016 AACR. Cancers are heterogeneous, comprising distinct tumor subtypes. Therefore, presenting the burden of cancer in the population and trends over time by these tumor subtypes is important to identify patterns and differences in the occurrence of these subtypes, especially to generalize findings to the U.S. general population. Using SEER Cancer Registry Data, we present incidence rates according to subtypes for diagnosis years (1992-2013) among men and women for five major cancer sites: breast (female only), esophagus, kidney and renal pelvis, lung and bronchus, and thyroid. We also describe estimates of 5-year relative survival according to subtypes and diagnosis year (1992-2008). We used Joinpoint models to identify years when incidence rate trends changed slope. Finally, recent 5-year age-adjusted incidence rates (2009-2013) are presented for each subtype by race and age. Hormone receptor-positive and HER2-negative was the most common subtype (about 74%) of breast cancers. Adenocarcinoma made up about 69% of esophagus cases among men. Adenocarcinoma also is the most common lung subtype (43% in men and 52% in women). Ninety percent of thyroid subtypes were papillary. Distinct incidence and survival patterns emerged by these subtypes over time among men and women. Histologic or molecular subtype revealed different incidence and/or survival trends that are masked when cancer is considered as a single disease on the basis of anatomic site. Presenting incidence and survival trends by subtype, whenever possible, is critical to provide more detailed and meaningful data to patients, providers, and the public. . |
| Author | Howlader, Nadia Penberthy, Lynne Lewis, Denise R Altekruse, Sean F Petkov, Valentina I Noone, Anne-Michelle Cronin, Kathleen A |
| Author_xml | – sequence: 1 givenname: Anne-Michelle surname: Noone fullname: Noone, Anne-Michelle email: noonea@mail.nih.gov organization: Division of Cancer Control and Population Sciences, Surveillance Research Program, National Cancer Institute, Bethesda, Maryland. noonea@mail.nih.gov – sequence: 2 givenname: Kathleen A surname: Cronin fullname: Cronin, Kathleen A organization: Division of Cancer Control and Population Sciences, Surveillance Research Program, National Cancer Institute, Bethesda, Maryland – sequence: 3 givenname: Sean F surname: Altekruse fullname: Altekruse, Sean F organization: Division of Cancer Control and Population Sciences, Surveillance Research Program, National Cancer Institute, Bethesda, Maryland – sequence: 4 givenname: Nadia surname: Howlader fullname: Howlader, Nadia organization: Division of Cancer Control and Population Sciences, Surveillance Research Program, National Cancer Institute, Bethesda, Maryland – sequence: 5 givenname: Denise R surname: Lewis fullname: Lewis, Denise R organization: Division of Cancer Control and Population Sciences, Surveillance Research Program, National Cancer Institute, Bethesda, Maryland – sequence: 6 givenname: Valentina I surname: Petkov fullname: Petkov, Valentina I organization: Division of Cancer Control and Population Sciences, Surveillance Research Program, National Cancer Institute, Bethesda, Maryland – sequence: 7 givenname: Lynne surname: Penberthy fullname: Penberthy, Lynne organization: Division of Cancer Control and Population Sciences, Surveillance Research Program, National Cancer Institute, Bethesda, Maryland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27956436$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkE1Lw0AQhhep2A_9CcoePZi6u8kk2aPUqoWCRdtz2N1MaiRf7iaF3vzpprWCh-F9GR4ehhmTQVVXSMg1Z1POIb7nDMCTMoTpfLXweOgxEOyMjDj4sRdFAIN_fUjGzn0yxiIJcEGGos8w8MMR-Z6pyqCli8rkKfaVqiql753d5TtV0LXFKnVU7_uVbvcN0o3Lqy19VK2ima1L2n7gEce8KA4qOm96UZnXRb3dH2Xzft7QdUXr6MrWW6vKO8qlFJ5g3L8k55kqHF6dckI2T_P17MVbvj4vZg9LzwCD1osDIXgWaBMGJoY4M9oXRiutA8x8EKglGJFJPwUfDEKaaQ4RjzAUypfSGDEht7_extZfHbo2KXNn8HA01p1LeAwiDCPBgx69OaGdLjFNGpuXyu6Tv6-JHx4bcbA |
| CitedBy_id | crossref_primary_10_1093_jnci_djae008 crossref_primary_10_1038_s41419_021_03858_7 crossref_primary_10_1016_j_jot_2025_05_001 crossref_primary_10_1097_CAD_0000000000001717 crossref_primary_10_3390_jpm11060518 crossref_primary_10_3390_antib9040067 crossref_primary_10_1016_j_clgc_2018_11_003 crossref_primary_10_1016_j_mayocp_2018_03_002 crossref_primary_10_1210_jendso_bvae084 crossref_primary_10_1016_j_canlet_2020_08_043 crossref_primary_10_3389_fonc_2021_646559 crossref_primary_10_3390_cancers11101570 crossref_primary_10_1542_pir_2021_005282 crossref_primary_10_1093_oncolo_oyad165 crossref_primary_10_3892_ol_2023_14110 crossref_primary_10_1158_2159_8290_CD_19_0487 crossref_primary_10_1016_j_athoracsur_2021_10_021 crossref_primary_10_3389_fendo_2020_00638 crossref_primary_10_1016_j_clgc_2019_08_009 crossref_primary_10_1089_end_2018_0046 crossref_primary_10_1002_cncr_32126 crossref_primary_10_1007_s10549_025_07694_7 crossref_primary_10_1007_s11095_018_2563_6 crossref_primary_10_1007_s00246_023_03192_z crossref_primary_10_1158_0008_5472_CAN_22_3464 crossref_primary_10_5114_pjr_2018_75017 crossref_primary_10_1002_jum_14610 crossref_primary_10_1186_s12885_024_13196_4 crossref_primary_10_1016_j_jbi_2022_104255 crossref_primary_10_1093_dote_doaa015 crossref_primary_10_1158_1541_7786_MCR_18_0047 crossref_primary_10_2147_CMAR_S343549 crossref_primary_10_3390_ijms23063067 crossref_primary_10_3390_medicina61061075 crossref_primary_10_1007_s10549_021_06449_4 crossref_primary_10_1002_jso_26149 crossref_primary_10_1007_s13304_020_00703_y crossref_primary_10_1053_j_seminoncol_2020_07_007 crossref_primary_10_3390_jpm12111874 crossref_primary_10_1080_1120009X_2023_2247206 crossref_primary_10_1002_pbc_29437 crossref_primary_10_1016_j_urolonc_2019_05_001 crossref_primary_10_1016_j_jconrel_2018_10_030 crossref_primary_10_1016_j_clbc_2021_05_008 crossref_primary_10_1007_s12032_025_02900_4 crossref_primary_10_3390_cancers12082164 crossref_primary_10_1016_j_mucimm_2024_03_007 crossref_primary_10_1016_j_beha_2020_101191 crossref_primary_10_3390_children9010070 crossref_primary_10_1016_j_cca_2025_120603 crossref_primary_10_3389_fonc_2022_983892 crossref_primary_10_1016_j_lungcan_2022_11_015 crossref_primary_10_1159_000545820 crossref_primary_10_4103_jcrt_jcrt_80_21 crossref_primary_10_1021_acsami_5c06626 crossref_primary_10_1007_s10549_020_05587_5 crossref_primary_10_1007_s11356_023_27876_4 crossref_primary_10_1080_14712598_2019_1665019 crossref_primary_10_1007_s10549_019_05250_8 crossref_primary_10_2147_ITT_S490075 crossref_primary_10_1055_s_0042_1760403 crossref_primary_10_1007_s10620_020_06241_2 crossref_primary_10_1111_bju_14841 crossref_primary_10_3892_ol_2019_10610 crossref_primary_10_1016_j_scitotenv_2024_169962 crossref_primary_10_1016_j_euo_2018_04_013 crossref_primary_10_3389_fonc_2022_836452 crossref_primary_10_3390_ijms241311153 crossref_primary_10_7759_cureus_76068 crossref_primary_10_1177_1049909120969963 crossref_primary_10_1097_MD_0000000000044313 crossref_primary_10_3390_jpm11010060 crossref_primary_10_1186_s12885_020_06902_5 crossref_primary_10_1371_journal_pone_0228968 crossref_primary_10_1016_j_euo_2018_10_010 crossref_primary_10_1097_MPH_0000000000002625 crossref_primary_10_1186_s13014_023_02365_7 crossref_primary_10_1016_j_critrevonc_2020_102981 crossref_primary_10_3390_ijms22126288 crossref_primary_10_1002_ctm2_652 crossref_primary_10_1016_j_ando_2020_11_006 crossref_primary_10_3389_fpubh_2022_790225 crossref_primary_10_1186_s12894_021_00876_7 crossref_primary_10_3390_ph15101295 crossref_primary_10_1089_dna_2020_5564 crossref_primary_10_1080_21655979_2021_1923259 crossref_primary_10_1016_j_clgc_2018_09_011 crossref_primary_10_1172_JCI150201 crossref_primary_10_1007_s11255_019_02284_1 crossref_primary_10_1177_17588359221081077 crossref_primary_10_1007_s00432_019_02860_z crossref_primary_10_1007_s12254_019_00548_1 crossref_primary_10_1016_j_hemonc_2017_02_001 crossref_primary_10_3390_cancers17111823 crossref_primary_10_1080_01913123_2017_1388322 crossref_primary_10_1088_1361_6560_ada5a6 crossref_primary_10_1016_j_gassur_2024_08_012 crossref_primary_10_1007_s00266_023_03290_6 crossref_primary_10_3389_fnut_2022_960674 crossref_primary_10_1007_s10549_020_06022_5 crossref_primary_10_4274_ejbh_galenos_2023_2022_12_4 crossref_primary_10_4103_jcrt_jcrt_125_22 crossref_primary_10_1016_S1470_2045_21_00580_5 crossref_primary_10_1016_j_clgc_2018_05_016 crossref_primary_10_3892_or_2023_8629 crossref_primary_10_1038_s41523_025_00722_1 crossref_primary_10_1093_dote_doac065 crossref_primary_10_1016_j_canlet_2020_05_034 crossref_primary_10_1016_j_intimp_2022_109447 crossref_primary_10_1093_jnci_djz202 crossref_primary_10_1016_j_ajpath_2019_04_007 crossref_primary_10_1016_j_heliyon_2024_e37744 crossref_primary_10_1097_OR9_0000000000000042 crossref_primary_10_3892_ol_2020_11517 crossref_primary_10_1016_j_critrevonc_2022_103582 crossref_primary_10_1002_ijc_31308 crossref_primary_10_1016_j_gene_2019_02_077 crossref_primary_10_1016_j_tjog_2021_05_010 crossref_primary_10_1007_s00423_024_03279_y crossref_primary_10_1016_j_jgo_2019_09_009 crossref_primary_10_1038_s41523_025_00751_w crossref_primary_10_1177_17588359231187201 crossref_primary_10_1016_j_surg_2019_03_041 crossref_primary_10_1097_PPO_0000000000000590 crossref_primary_10_2217_fon_2020_0996 crossref_primary_10_17650_2782_3202_2024_4_4_47_52 crossref_primary_10_3390_cells10112988 crossref_primary_10_1016_j_gene_2020_145068 crossref_primary_10_1183_16000617_0156_2024 crossref_primary_10_1016_j_cpet_2021_12_002 crossref_primary_10_1158_1078_0432_CCR_19_2896 crossref_primary_10_1007_s12032_025_02737_x crossref_primary_10_1177_1758835919891652 crossref_primary_10_1002_hon_2918 crossref_primary_10_1007_s12011_020_02186_9 crossref_primary_10_1177_000313481708300731 crossref_primary_10_1186_s13046_020_01653_4 crossref_primary_10_1257_aer_20201480 crossref_primary_10_3390_cancers14235760 crossref_primary_10_1186_s12916_024_03319_w crossref_primary_10_3389_fcvm_2022_850674 crossref_primary_10_1002_cncr_31315 crossref_primary_10_1038_s41379_022_01025_7 crossref_primary_10_1186_s12916_021_02118_x crossref_primary_10_1038_s41598_024_61748_2 crossref_primary_10_1016_j_euf_2018_01_009 crossref_primary_10_1158_1078_0432_CCR_19_0463 crossref_primary_10_1038_s41598_023_38200_y crossref_primary_10_1016_j_clgc_2019_07_008 crossref_primary_10_1002_tox_23786 crossref_primary_10_1038_s41568_021_00406_5 crossref_primary_10_2147_IJN_S375950 crossref_primary_10_3390_cancers13102314 crossref_primary_10_1186_s12859_021_04279_1 crossref_primary_10_1200_JCO_18_01933 crossref_primary_10_1080_09553002_2021_1913527 crossref_primary_10_2147_IJGM_S345336 crossref_primary_10_3389_fonc_2021_698732 crossref_primary_10_3892_ijo_2019_4825 crossref_primary_10_1007_s12022_017_9509_0 crossref_primary_10_3389_fonc_2021_710585 crossref_primary_10_3389_fendo_2022_915135 crossref_primary_10_1002_humu_23378 crossref_primary_10_1007_s12672_025_03103_z crossref_primary_10_1016_j_tranon_2021_101260 crossref_primary_10_1080_14737159_2021_1947798 crossref_primary_10_1016_j_ctrv_2020_102015 crossref_primary_10_3390_app9173589 crossref_primary_10_3892_ol_2021_13141 crossref_primary_10_1016_j_cllc_2019_04_004 crossref_primary_10_1007_s40830_022_00379_w crossref_primary_10_1002_mp_12637 crossref_primary_10_1007_s00345_018_2310_y crossref_primary_10_1002_cam4_3143 crossref_primary_10_1097_JU9_0000000000000127 crossref_primary_10_1016_j_envpol_2021_117376 crossref_primary_10_3389_fonc_2019_01577 crossref_primary_10_1146_annurev_cancerbio_030518_055719 crossref_primary_10_1158_0008_5472_CAN_23_0705 crossref_primary_10_1016_j_breast_2020_06_008 crossref_primary_10_1016_j_urolonc_2017_10_012 crossref_primary_10_3390_cancers13184670 crossref_primary_10_3233_BD_220018 crossref_primary_10_1186_s12885_024_13033_8 crossref_primary_10_1016_j_anndiagpath_2022_152017 crossref_primary_10_1097_CEJ_0000000000000614 crossref_primary_10_1080_10810730_2018_1506836 crossref_primary_10_1016_j_ejso_2019_01_218 crossref_primary_10_1080_09674845_2020_1741249 crossref_primary_10_1097_RUQ_0000000000000671 crossref_primary_10_1007_s10147_025_02800_7 crossref_primary_10_1007_s00345_017_2093_6 crossref_primary_10_4158_EP_2018_0173 crossref_primary_10_1016_j_canep_2018_08_006 crossref_primary_10_1007_s11764_021_01011_z crossref_primary_10_1007_s10653_022_01261_5 crossref_primary_10_1007_s12029_018_0089_0 crossref_primary_10_4049_jimmunol_1901208 crossref_primary_10_1007_s12672_025_02052_x crossref_primary_10_1080_17437199_2022_2162947 crossref_primary_10_1002_agm2_12382 crossref_primary_10_1007_s11255_017_1744_2 crossref_primary_10_1136_jclinpath_2018_205396 crossref_primary_10_3390_life14010022 crossref_primary_10_1016_j_canep_2018_11_007 crossref_primary_10_3390_nano8110884 crossref_primary_10_1089_lrb_2020_0126 crossref_primary_10_1186_s12905_022_01882_z crossref_primary_10_1002_cam4_2350 crossref_primary_10_1007_s10238_022_00888_z crossref_primary_10_1016_j_fertnstert_2021_01_044 crossref_primary_10_1016_j_rbmo_2020_10_001 crossref_primary_10_1016_j_bioadv_2022_212725 crossref_primary_10_1016_j_urolonc_2019_09_015 crossref_primary_10_1177_1849454419899214 crossref_primary_10_1089_ct_2017_29_351_353 crossref_primary_10_1016_j_ygyno_2021_07_033 crossref_primary_10_1007_s00345_019_02927_z crossref_primary_10_1007_s40615_022_01460_x crossref_primary_10_1186_s12885_022_09895_5 crossref_primary_10_3390_diagnostics13172748 crossref_primary_10_1055_a_2238_3199 crossref_primary_10_4103_ijnm_IJNM_52_18 crossref_primary_10_1002_pbc_30574 crossref_primary_10_1080_14737140_2021_1908132 crossref_primary_10_2147_CMAR_S286503 crossref_primary_10_1002_cam4_4785 crossref_primary_10_1038_s41416_018_0047_4 crossref_primary_10_1016_j_bbrc_2018_02_020 crossref_primary_10_5507_bp_2020_015 crossref_primary_10_1016_j_urolonc_2017_06_060 crossref_primary_10_3390_cimb46080471 crossref_primary_10_1016_j_envres_2020_110333 crossref_primary_10_3390_diagnostics13142328 crossref_primary_10_1186_s12943_019_1007_1 crossref_primary_10_1093_jncimonographs_lgae022 crossref_primary_10_1002_ijc_31258 crossref_primary_10_1111_cen_14431 crossref_primary_10_1016_j_clgc_2019_04_009 crossref_primary_10_3390_cancers12102894 crossref_primary_10_1186_s12885_022_09300_1 crossref_primary_10_1186_s12951_023_02270_x crossref_primary_10_18027_2224_5057_2018_8_3_5_12 crossref_primary_10_1111_cts_12802 crossref_primary_10_1080_15384101_2025_2540139 crossref_primary_10_3390_antiox12020457 crossref_primary_10_1016_j_ejca_2025_115409 crossref_primary_10_1002_jbt_70276 crossref_primary_10_1158_1078_0432_CCR_20_4162 |
| ContentType | Journal Article |
| Copyright | 2016 American Association for Cancer Research. |
| Copyright_xml | – notice: 2016 American Association for Cancer Research. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1158/1055-9965.EPI-16-0520 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1538-7755 |
| ExternalDocumentID | 27956436 |
| Genre | Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: Intramural NIH HHS grantid: Z99 CA999999 |
| GroupedDBID | --- .55 18M 29B 2FS 2WC 34G 39C 3O- 53G 5GY 5VS 6J9 AAFWJ ABOCM ACPRK ADBBV ADCOW AENEX AFHIN AFRAH AI. ALMA_UNASSIGNED_HOLDINGS BR6 BTFSW C1A CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P FRP H13 H~9 IH2 KQ8 L7B NPM OK1 P2P PQQKQ QTD RCR RHI SJN UDS VH1 W8F WHG WOQ X7M ZXP 7X8 |
| ID | FETCH-LOGICAL-c505t-84221f4bc64c858fcb32cbabb4ef352eb95c2f93d535ce5dfb15717e62a399cc2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 314 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000398815100022&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1538-7755 |
| IngestDate | Thu Jul 10 22:10:18 EDT 2025 Mon Jul 21 06:01:43 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| License | 2016 American Association for Cancer Research. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c505t-84221f4bc64c858fcb32cbabb4ef352eb95c2f93d535ce5dfb15717e62a399cc2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://doi.org/10.1158/1055-9965.EPI-16-0520 |
| PMID | 27956436 |
| PQID | 1852667214 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1852667214 pubmed_primary_27956436 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-04-01 |
| PublicationDateYYYYMMDD | 2017-04-01 |
| PublicationDate_xml | – month: 04 year: 2017 text: 2017-04-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Cancer epidemiology, biomarkers & prevention |
| PublicationTitleAlternate | Cancer Epidemiol Biomarkers Prev |
| PublicationYear | 2017 |
| SSID | ssj0007955 |
| Score | 2.646002 |
| SecondaryResourceType | review_article |
| Snippet | Cancers are heterogeneous, comprising distinct tumor subtypes. Therefore, presenting the burden of cancer in the population and trends over time by these tumor... Background: Cancers are heterogeneous, comprising distinct tumor subtypes. Therefore, presenting the burden of cancer in the population and trends over time by... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 632 |
| SubjectTerms | Humans Incidence Male Neoplasms - epidemiology Neoplasms - mortality Neoplasms - pathology Population Surveillance SEER Program - statistics & numerical data Survival Analysis United States - epidemiology |
| Title | Cancer Incidence and Survival Trends by Subtype Using Data from the Surveillance Epidemiology and End Results Program, 1992-2013 |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/27956436 https://www.proquest.com/docview/1852667214 |
| Volume | 26 |
| WOSCitedRecordID | wos000398815100022&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3LS8MwGA_qRLz4fswXETwa16ZJk55EdEMPG8MH7DaSNAFBurluwm7-6X5JO3YSBA_toeQLJd_rl-RLfghdabCKPMojArnYEMhQhkgFfkVdBgKpsE6YQDYhej05GGT9esGtrMsqFzExBOp8ZPwaecsf8k1TmK-w2_En8axRfne1ptBYRY0EoIy3ajFY3hYussB6GpxaCM7rEzwxly3PC0kA6_Obdv-JxDCr5jT6HWWGbNPZ_u9_7qCtGmfiu8owdtGKLfbQRrfeSd9H3_de3RMM8aGiFcWqyPHLDCIH2B6uSmWxnsMn7ZdpcagtwA9qqrA_koIBOIbm1tMWefn2kmt2Hjprw_Nsy9nHtMT9qgzsGoc6VIADyQF667Rf7x9JzcZADKCkKZGM0tgxbVJmJJfO6IQarbRm1gGKszrjBjSc5DzhxvLc6ZjDXNGmVIFmjKGHaK0YFfYYYcF0IgzjjpmMWcqk0jxjynEHPUUya6LLxdgOwdr9FoYq7GhWDpej20RHlYKG4-pajiEFdQO-Sk_-IH2KNqnPz6EE5ww1HPi6PUfr5mv6Xk4ughnBu9fv_gAWLtDL |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cancer+Incidence+and+Survival+Trends+by+Subtype+Using+Data+from+the+Surveillance+Epidemiology+and+End+Results+Program%2C+1992-2013&rft.jtitle=Cancer+epidemiology%2C+biomarkers+%26+prevention&rft.au=Noone%2C+Anne-Michelle&rft.au=Cronin%2C+Kathleen+A&rft.au=Altekruse%2C+Sean+F&rft.au=Howlader%2C+Nadia&rft.date=2017-04-01&rft.eissn=1538-7755&rft.volume=26&rft.issue=4&rft.spage=632&rft_id=info:doi/10.1158%2F1055-9965.EPI-16-0520&rft_id=info%3Apmid%2F27956436&rft_id=info%3Apmid%2F27956436&rft.externalDocID=27956436 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-7755&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-7755&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-7755&client=summon |